Continuing Education Activity

Infections caused by free-living amebas are rare but often devastating and can involve the central nervous system, eyes, skin, and other organs. Pathogenic free-living amebas, including Acanthamoeba species, Naegleria fowleri, Balamuthia mandrillaris, and, rarely, Sappinia pedata, are widely distributed in the environment and can cause severe disease in both immunocompetent and immunocompromised individuals. Clinical syndromes range from primary amebic meningoencephalitis, a fulminant and rapidly fatal illness, to granulomatous amebic encephalitis, a subacute or chronic condition that often presents with focal neurologic deficits and mass-like brain lesions, as well as Acanthamoeba keratitis and disseminated cutaneous disease. These infections are frequently underrecognized due to their rarity, nonspecific clinical presentations, and resemblance to more common infectious, inflammatory, or neoplastic conditions.

Delays in diagnosis are common and contribute significantly to the high morbidity and mortality associated with central nervous system involvement. Management is further complicated by the absence of standardized treatment regimens and reliance on prolonged multidrug therapy guided by limited clinical evidence. This activity reviews the epidemiology, risk factors, microbiology, and pathophysiology of free-living amebic infections and provides clinicians with practical guidance on clinical presentation, diagnostic evaluation, and management strategies. The activity also emphasizes prevention measures, including water safety and contact lens hygiene, and highlights the critical role of interprofessional collaboration in early recognition, treatment coordination, and patient and family counseling to improve outcomes.

Objectives:

• Identify the epidemiology, environmental exposures, and host risk factors associated with infections caused by free-living amebas, including Acanthamoeba, Naegleria fowleri, Balamuthia mandrillaris, and Sappinia pedata.
• Differentiate the clinical presentations and diagnostic features of primary amebic meningoencephalitis, granulomatous amebic encephalitis, Acanthamoeba keratitis, and disseminated amoebic infections from other infectious, inflammatory, and neoplastic conditions.
• Apply evidence-informed diagnostic and management strategies, including appropriate use of neuroimaging, tissue biopsy, molecular testing, and prolonged combination antimicrobial therapy, in patients with suspected free-living amebic infection.
• Collaborate effectively within an interprofessional healthcare team to facilitate early recognition, timely treatment initiation, patient and family communication, and implementation of preventive and public health measures related to free-living amebic infections.

Access free multiple choice questions on this topic.

Introduction

Free-living amebas are ubiquitous protozoa found in soil, freshwater, dust, and man-made water systems. Unlike obligate parasites, these organisms typically survive independently in the environment but may opportunistically infect humans. Although rare, infections caused by free-living amebas are associated with high morbidity and mortality. The primary pathogenic genera implicated in human disease include Acanthamoeba species, Naegleria fowleri, Balamuthia mandrillaris, and Sappinia pedata.[1]

Acanthamoeba species and B mandrillaris are most commonly associated with granulomatous amebic encephalitis (GAE), which is a subacute to chronic inflammatory disease of the central nervous system (CNS) that often manifests radiographically as one or more space-occupying lesions and may clinically mimic neoplasms or other chronic infections. In contrast, N fowleri causes primary amebic meningoencephalitis (PAM)—an acute, rapidly progressive infection characterized by fulminant meningoencephalitis.

In addition to CNS disease, Acanthamoeba species are well recognized as a cause of keratitis, and both Acanthamoeba species and B mandrillaris may involve the skin and lungs. Infections due to free-living amebas pose significant diagnostic and therapeutic challenges due to nonspecific presentations, limited familiarity among clinicians, and a lack of standardized treatment regimens. Early recognition is critical, as delayed diagnosis is a major contributor to poor outcomes.

Etiology

The 4 genera of amebas that cause disease in humans are Acanthamoeba spp., N fowleri, B mandrillaris, and S pedata. All of these species cause CNS infections, but Acanthamoeba spp. may cause localized extra-CNS infections in immunocompetent hosts or disseminated infections in immunocompromised hosts.[1] All these pathogenic free-living amebas exist in 2 primary forms: an active trophozoite stage responsible for tissue invasion and a dormant cyst stage that is highly resistant to environmental stressors and antimicrobial therapy. N fowleri additionally exhibits a transient flagellated form.[2][3][4]

Epidemiology

Free-living amebas are distributed globally and have been isolated from natural bodies of water, soil, air, and artificial environments such as swimming pools, plumbing systems, contact lens solutions, and hospital water supplies.[5] Identifying the exact source of infection is often difficult, as exposure may precede clinical disease by weeks or months.[2] Certain populations appear to be at increased risk. For example, invasive infections involving the CNS or skin caused by Acanthamoeba species and B mandrillaris are more frequently observed in individuals with diabetes mellitus, HIV infection, or a history of solid organ transplant. Epidemiological data further suggest that Balamuthia infection occurs disproportionately among individuals of Hispanic ethnicity, although the reasons for this increased susceptibility remain unclear.[6][2]

Acanthamoeba Species

Acanthamoeba species are widely distributed in natural and artificial environments, including tap water, soil, air, contact lens solutions, and hospital water systems. This microorganism has been found in fresh, brackish, and seawater as well as sewage, swimming pools, and contact lens supplies.[5][7] Predisposing conditions include diabetes mellitus, alcoholism, cirrhosis, HIV infection, chronic renal failure, systemic lupus erythematosus, malignant neoplasm, chemotherapy, and organ transplant, including hematopoietic cell and solid organ transplant.[2]

Naegleria fowleri

N fowleri is a thermophilic ameboflagellate found in warm freshwater such as lakes, hot springs, and poorly chlorinated pools. The infection primarily affects children and young adults in the summer months. The organism can tolerate temperatures up to 45 °C and has therefore been identified in the thermal discharges of power plants and geothermal wells. Infection is typically acquired during recreational water exposure when contaminated water enters the nasal passages, generally during swimming or sinus irrigation, and migrates to the brain. The infection causes PAM—a rapidly progressive and often fatal disease.[8]

Balamuthia mandrillaris

B mandrillaris is a soil-associated ameba that can cause severe CNS and disseminated disease. Unlike Naegleria and Acanthamoeba infections, hematogenous dissemination occurs through skin wounds or inhalation of contaminated dust. Cases have also been reported following solid organ transplant from infected donors. Both immunocompetent and immunocompromised individuals may be affected.[4][6]

Sappinia pedata

S pedata is an exceptionally rare cause of human infection, with only a single confirmed case of GAE reported in the literature. The infection occurred in an immunocompetent farmer aged 38 with regular exposure to livestock and no underlying immunosuppression. Neuroimaging revealed a solitary focal brain lesion, and histopathological examination demonstrated large, binucleate trophozoites consistent with Sappinia species. Although the precise route of infection could not be definitively established, inhalation was considered the most likely mechanism, as the organism has been isolated from soil contaminated with animal feces.[9]

Pathophysiology

Trophozoites adhere to host tissues through specific surface-binding proteins and produce a variety of cytotoxic enzymes, including proteases, phospholipases, and metalloproteinases, that facilitate tissue destruction and invasion. Acanthamoeba spp. and B mandrillaris are capable of hematogenous dissemination after entry through the skin or respiratory tract, ultimately crossing the blood–brain barrier and causing CNS disease. In contrast, N fowleri organisms gain access to the CNS by migrating along the olfactory nerves following nasal exposure, resulting in rapid cerebral invasion.[10] 

Host immune responses vary depending on the organism and disease course. Granulomatous inflammation and cell-mediated immunity are characteristic of Acanthamoeba and Balamuthia infections. In contrast, the fulminant nature of Naegleria infection precludes the development of an effective adaptive immune response.[11][12]

History and Physical

Primary Amebic Meningoencephalitis

PAM is caused by N fowleri and is an acute, rapidly progressive disease that primarily affects children and young adults. Symptoms typically develop within days of exposure and include fever, severe headache, nausea, vomiting, neck stiffness, photophobia, and altered mental status. Neurological deterioration occurs rapidly, progressing to seizures, coma, cerebral edema, and death, often within one week of symptom onset.[10]

Granulomatous Amebic Encephalitis

GAE is caused by Acanthamoeba spp. or B mandrillaris and typically follows an indolent yet progressive course, with symptoms evolving over several weeks to months. Patients commonly develop persistent headaches, intermittent low-grade fevers, visual complaints, changes in behavior or cognition, and focal neurological deficits that correspond to the anatomic distribution of cerebral lesions.[13] The latency between exposure and symptom onset is often unclear, as the initial acquisition frequently goes unrecognized. In individuals with HIV infection, GAE may present with focal brain lesions that resemble toxoplasmic encephalitis on imaging; however, in contrast to toxoplasmosis, these lesions do not improve with standard antitoxoplasma therapy. With continued disease progression, patients may develop seizures, increasing intracranial pressure, diminished consciousness, and ultimately, coma and death.[2]

In cases associated with B mandrillaris, patients may describe a preceding cutaneous lesion, often weeks or months before neurological symptoms develop. These skin lesions may be painless and slow growing, contributing to underrecognition of their clinical significance. Respiratory symptoms or sinus complaints are occasionally reported and may represent an initial portal of entry before hematogenous dissemination.[14]

Acanthamoeba Keratitis

Acanthamoeba keratitis is a painful, vision-threatening corneal infection most commonly affecting patients using contact lenses, particularly those with poor lens hygiene or exposure to nonsterile water. Patients typically present with redness, excessive tearing, a sensation of a foreign body in the eye, ocular pain, and sensitivity to light. The infection is usually unilateral, although bilateral involvement has been reported. Epithelial surface irregularities and pseudodendritic lesions may mark early disease, while advanced infection is classically associated with the development of a ring-shaped stromal infiltrate. Delayed diagnosis may result in corneal scarring or blindness.[7]

Cutaneous and Disseminated Disease

Both Acanthamoeba and Balamuthia infections can cause cutaneous lesions and may present as nodules, plaques, ulcers, or necrotic lesions, particularly in immunocompromised patients. Disseminated disease may involve the lungs, sinuses, kidneys, adrenal glands, or bones and may precede or accompany CNS involvement.[1][6]

Evaluation

Diagnosis of infections caused by free-living amebas requires a high index of suspicion. Initial evaluation often includes neuroimaging, which may reveal nonspecific findings such as edema, hemorrhage, or ring-enhancing lesions. The temporal and parietal lobes are most commonly affected. Definitive diagnosis relies on microscopic examination, histopathological evaluation, and molecular testing. Trophozoites may be visualized in cerebrospinal fluid in PAM but are rarely detected in GAE. The diagnosis of GAE is established by brain tissue biopsy, which demonstrates necrotizing or granulomatous inflammation with trophozoites and cysts on hematoxylin-eosin staining. For patients with skin or pulmonary lesions, tissue samples should be obtained to evaluate for trophozoites.[1] Polymerase chain reaction (PCR) assays provide high sensitivity and specificity and are available through specialized reference laboratories. Confocal microscopy is particularly useful in the evaluation of suspected Acanthamoeba keratitis.

Treatment / Management

Randomized controlled trial data to guide therapy are not available, and treatment recommendations are based on case series and expert opinion. Management typically involves early initiation of combination antimicrobial therapy.[15][16]

• PAM is treated with aggressive multidrug regimens centered on conventional amphotericin B, often combined with miltefosine, fluconazole, rifampin, and azithromycin.[10]
• GAE requires prolonged combination therapy, frequently including pentamidine, fluconazole, and miltefosine. Trimethoprim-sulfamethoxazole, metronidazole, and azithromycin may also be added to the regimen. Acanthamoeba spp. are generally resistant to amphotericin B.
• Acanthamoeba keratitis is managed with topical polyhexamethylene biguanide (0.02%) or biguanide-chlorhexidine in combination with propamidine (0.1%) or hexamidine (0.1%). Surgical intervention may be necessary in refractory cases.[7][17]
• Optimal therapy for B mandrillaris infection has not been clearly established, as the available evidence is largely derived from case reports and small series. In the United States, survivors have most commonly received combination regimens centered on pentamidine, flucytosine, fluconazole, and a macrolide (either azithromycin or clarithromycin), often with the addition of sulfadiazine, miltefosine, thioridazine, or liposomal amphotericin B. Nitroxoline has been recently reported to be successful in the treatment of B mandrillaris encephalitis.[18]
• A patient with GAE due to Sappinia spp. was treated with a combination of azithromycin, intravenous pentamidine, itraconazole, and flucytosine and survived.[9]

Consultation with infectious disease specialists and the Centers for Disease Control and Prevention (CDC) is strongly recommended for any suspected case of infection due to free-living amebas to assist with diagnostic confirmation and therapeutic guidance.[16]

Differential Diagnosis

PAM caused by N fowleri may initially mimic acute bacterial meningitis due to overlapping clinical features and cerebrospinal fluid findings. However, PAM is characterized by rapid progression and a diffuse meningoencephalitic process, whereas GAE follows a more indolent course and presents with focal neurological deficits and granulomatous inflammation. As a result, patients with PAM are frequently treated empirically for bacterial meningitis early in the disease course, while GAE is more often mistaken for conditions that cause space-occupying CNS lesions.[19][20]

The differential diagnosis of GAE is extensive because the disease typically presents with subacute or chronic focal neurological deficits and mass-like brain lesions, particularly in immunocompromised patients. Because symptoms are nonspecific and progression is gradual, GAE is frequently misdiagnosed as malignant neoplasms, vasculitis, or other infectious or inflammatory neurological conditions.[13] Important diagnostic considerations include bacterial brain abscess, CNS tuberculosis, nocardiosis, invasive aspergillosis, cryptococcal meningoencephalitis, and CNS histoplasmosis. Parasitic and neoplastic processes such as toxoplasmosis, neurocysticercosis, and primary CNS lymphoma should also be considered, particularly in patients with compatible risk factors and unexplained focal neurological findings.[14]

Prognosis

GAE carries an extremely poor prognosis, with reported mortality rates exceeding 90%, regardless of the causative organism (Acanthamoeba spp. or B mandrillaris). Outcomes are similarly devastating for PAM, which is associated with case-fatality rates approaching 99% and a rapidly progressive course, with death typically occurring within days of symptom onset.[14][19] Unfavorable outcomes are largely attributable to the nonspecific clinical presentation and frequent delays in diagnosis, which often occur only after advanced CNS involvement. Many cases are identified postmortem, further highlighting the diagnostic challenges associated with this disease.[20]

Survival has been reported in a small number of patients and is most often associated with early recognition, prompt initiation of combination antimicrobial therapy, and, in select cases, surgical resection of localized lesions. Even among survivors, long-term neurological sequelae are common, including cognitive impairment, motor deficits, and seizure disorders, underscoring the need for early interdisciplinary care and prolonged follow-up.[20]

Complications

PAM results in rapid cerebral edema, increased intracranial pressure, brain herniation, and profound neurological deterioration, frequently leading to death within days of symptom onset.[19] GAE may cause a more subacute course but is complicated by focal neurological deficits, seizures, altered mental status, and progressive brain necrosis, particularly in immunocompromised hosts. Acanthamoeba keratitis can cause corneal perforation and blindness.[7] Disseminated infection can involve the skin, lungs, kidneys, and sinuses, leading to ulcerative skin lesions, respiratory failure, and multiorgan dysfunction.

Consultations

Affected patients are treated by emergency physicians, internal medicine or pediatric specialists, neurologists, neurosurgeons, and infectious disease consultants.

Deterrence and Patient Education

Preventive counseling has a critical role in reducing the risk of infection. Individuals should avoid nasal exposure to warm freshwater, including lakes, rivers, hot springs, and untreated tap water; using nose clips or avoiding underwater activities may further reduce the risk of exposure.[21] Nasal irrigation devices should only be used with sterile, distilled, or previously boiled water.[22][23] Contact lens users should follow strict hygiene practices, including handwashing before handling lenses, avoiding exposure to water while wearing lenses, and using only recommended cleaning solutions. Patients with chronic skin wounds or immunosuppression should promptly report nonhealing skin lesions.[7][24]

Enhancing Healthcare Team Outcomes

Improving outcomes for infections caused by free-living amebas depends on early recognition, prompt diagnostic evaluation, and coordinated interdisciplinary care, as these rare infections are frequently misdiagnosed and associated with high mortality. Patients with suspected GAE or PAM should be managed at centers with advanced neurological and critical care capabilities. Close collaboration among infectious disease specialists, neurologists, neurosurgeons, intensivists, neuroradiologists, pathologists, and clinical microbiologists is essential, particularly because a brain or skin biopsy is often required to establish the diagnosis of GAE, and organisms may be difficult to identify on routine microscopy. Pharmacists play a key role in managing prolonged multidrug regimens, monitoring for drug toxicity and interactions, and facilitating access to agents such as miltefosine through the CDC. Critical care nurses and intensivists provide close neurologic monitoring and manage intracranial complications, while social workers support family communication and long-term care planning.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Visvesvara GS, Moura H, Schuster FL. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol. 2007 Jun;50(1):1-26. [PubMed: 17428307]

2.

Haston JC, O'Laughlin K, Matteson K, Roy S, Qvarnstrom Y, Ali IKM, Cope JR. The Epidemiology and Clinical Features of Non-Keratitis Acanthamoeba Infections in the United States, 1956-2020. Open Forum Infect Dis. 2023 Jan;10(1):ofac682. [PMC free article: PMC9835757] [PubMed: 36655187]

3.

Martinez AJ, Visvesvara GS. Free-living, amphizoic and opportunistic amebas. Brain Pathol. 1997 Jan;7(1):583-98. [PMC free article: PMC8098488] [PubMed: 9034567]

4.

Bhosale NK, Parija SC. Balamuthia mandrillaris: An opportunistic, free-living ameba - An updated review. Trop Parasitol. 2021 Jul-Dec;11(2):78-88. [PMC free article: PMC8579774] [PubMed: 34765527]

5.

Peña-Prunell MD, Reyes-Batlle M, Pérez-Pérez P, Rodríguez-Expósito RL, Sifaoui I, García-Pérez O, Domínguez-de Barros AT, Córdoba-Lanús E, Piñero JE, Lorenzo-Morales J. Molecular and Culture-Based Surveillance of Free-Living Amoebae in Human Related Sources in an Outermost Region. Pathogens. 2026 Jan 09;15(1) [PMC free article: PMC12844781] [PubMed: 41599058]

6.

Cope JR, Landa J, Nethercut H, Collier SA, Glaser C, Moser M, Puttagunta R, Yoder JS, Ali IK, Roy SL. The Epidemiology and Clinical Features of Balamuthia mandrillaris Disease in the United States, 1974-2016. Clin Infect Dis. 2019 May 17;68(11):1815-1822. [PMC free article: PMC7453664] [PubMed: 30239654]

7.

Lorenzo-Morales J, Khan NA, Walochnik J. An update on Acanthamoeba keratitis: diagnosis, pathogenesis and treatment. Parasite. 2015;22:10. [PMC free article: PMC4330640] [PubMed: 25687209]

8.

Jahangeer M, Mahmood Z, Munir N, Waraich UE, Tahir IM, Akram M, Ali Shah SM, Zulfqar A, Zainab R. Naegleria fowleri: Sources of infection, pathophysiology, diagnosis, and management; a review. Clin Exp Pharmacol Physiol. 2020 Feb;47(2):199-212. [PubMed: 31612525]

9.

Gelman BB, Rauf SJ, Nader R, Popov V, Borkowski J, Chaljub G, Nauta HW, Visvesvara GS. Amoebic encephalitis due to Sappinia diploidea. JAMA. 2001 May 16;285(19):2450-1. [PubMed: 11368696]

10.

Güémez A, García E. Primary Amoebic Meningoencephalitis by Naegleria fowleri: Pathogenesis and Treatments. Biomolecules. 2021 Sep 06;11(9) [PMC free article: PMC8469197] [PubMed: 34572533]

11.

Baig AM. Pathogenesis of amoebic encephalitis: Are the amoebae being credited to an 'inside job' done by the host immune response? Acta Trop. 2015 Aug;148:72-6. [PubMed: 25930186]

12.

Sarink MJ, van der Meijs NL, Denzer K, Koenderman L, Tielens AGM, van Hellemond JJ. Three encephalitis-causing amoebae and their distinct interactions with the host. Trends Parasitol. 2022 Mar;38(3):230-245. [PubMed: 34758928]

13.

Kalra SK, Sharma P, Shyam K, Tejan N, Ghoshal U. Acanthamoeba and its pathogenic role in granulomatous amebic encephalitis. Exp Parasitol. 2020 Jan;208:107788. [PubMed: 31647916]

14.

Lee DC, Fiester SE, Madeline LA, Fulcher JW, Ward ME, Schammel CM, Hakimi RK. Acanthamoeba spp. and Balamuthia mandrillaris leading to fatal granulomatous amebic encephalitis. Forensic Sci Med Pathol. 2020 Mar;16(1):171-176. [PubMed: 31773473]

15.

Baig AM. "Proposals for Amendments in the Diagnosis and Treatment of Encephalitis caused by Free-living Amoebae". Infect Disord Drug Targets. 2020;20(2):115-121. [PubMed: 30961516]

16.

Spottiswoode N, Haston JC, Hanners NW, Gruenberg K, Kim A, DeRisi JL, Wilson MR. Challenges and advances in the medical treatment of granulomatous amebic encephalitis. Ther Adv Infect Dis. 2024 Jan-Dec;11:20499361241228340. [PMC free article: PMC10838035] [PubMed: 38312848]

17.

Dart JK, Saw VP, Kilvington S. Acanthamoeba keratitis: diagnosis and treatment update 2009. Am J Ophthalmol. 2009 Oct;148(4):487-499.e2. [PubMed: 19660733]

18.

Spottiswoode N, Pet D, Kim A, Gruenberg K, Shah M, Ramachandran A, Laurie MT, Zia M, Fouassier C, Boutros CL, Lu R, Zhang Y, Servellita V, Bollen A, Chiu CY, Wilson MR, Valdivia L, DeRisi JL. Successful Treatment of Balamuthia mandrillaris Granulomatous Amebic Encephalitis with Nitroxoline. Emerg Infect Dis. 2023 Jan;29(1):197-201. [PMC free article: PMC9796214] [PubMed: 36573629]

19.

Capewell LG, Harris AM, Yoder JS, Cope JR, Eddy BA, Roy SL, Visvesvara GS, Fox LM, Beach MJ. Diagnosis, Clinical Course, and Treatment of Primary Amoebic Meningoencephalitis in the United States, 1937-2013. J Pediatric Infect Dis Soc. 2015 Dec;4(4):e68-75. [PubMed: 26582886]

20.

Matanock A, Mehal JM, Liu L, Blau DM, Cope JR. Estimation of Undiagnosed Naegleria fowleri Primary Amebic Meningoencephalitis, United States¹. Emerg Infect Dis. 2018 Jan;24(1):162-164. [PMC free article: PMC5749439] [PubMed: 29260676]

21.

K HC, Sajini DV, T NS, K FS, Najeem H. Primary Amoebic Meningoencephalitis: A Silent Killer from natural water sources. Infect Dis Now. 2026 Jan;56(1):105207. [PubMed: 41314470]

22.

Smith OA, Tillman W, Lewis JB, White S, Mattioli M, Haston J, Dorris M, Kahler A, Roundtree A, Ali IK, Roy S, Yakubik T, Sisco L, Kunz J. Notes from the Field: Primary Amebic Meningoencephalitis Associated with Nasal Irrigation Using Water from a Recreational Vehicle - Texas, 2024. MMWR Morb Mortal Wkly Rep. 2025 May 29;74(19):334-335. [PMC free article: PMC12121732] [PubMed: 40440212]

23.

Yoder JS, Straif-Bourgeois S, Roy SL, Moore TA, Visvesvara GS, Ratard RC, Hill VR, Wilson JD, Linscott AJ, Crager R, Kozak NA, Sriram R, Narayanan J, Mull B, Kahler AM, Schneeberger C, da Silva AJ, Poudel M, Baumgarten KL, Xiao L, Beach MJ. Primary amebic meningoencephalitis deaths associated with sinus irrigation using contaminated tap water. Clin Infect Dis. 2012 Nov;55(9):e79-85. [PMC free article: PMC11307261] [PubMed: 22919000]

24.

Arshad M, Carnt N, Tan J, Ekkeshis I, Stapleton F. Water Exposure and the Risk of Contact Lens-Related Disease. Cornea. 2019 Jun;38(6):791-797. [PubMed: 30789440]

Disclosure: Vini Vijayan declares no relevant financial relationships with ineligible companies.

Disclosure: Debbie Tristram declares no relevant financial relationships with ineligible companies.

Disclosure: Arayamparambil Anilkumar declares no relevant financial relationships with ineligible companies.